Skip to contentB
BridgeBio Pharma, Inc.
B
BBIOBridgeBio Pharma, Inc. Q1 2024 · 10-Q
Revenue$211.12M$211.12M+11,461.9% vs Q1 2023 Net Income-$36.16M-$36.16MN/M vs Q1 2023 EPS Diluted-$0.20-$0.20N/M vs Q1 2023 Operating Income$343,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BridgeBio Pharma, Inc. · CIK 1743881 · Engraved from SEC EDGAR
Free Cash Flowderived-$220,232,000N/M Margins · derivedOperating margin0.2%+6909.4 pt vs Q1 2023
Net margin-17.1%+7799.5 pt vs Q1 2023
ended Mar 31, 2024 · filed May 2, 2024 · 32 d after period end